EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Metabolomics and lipidomics strategies in modern drug discovery and development

Giuseppe Astarita, Rachel S Kelly, Jessica Lasky-Su

Drug Discovery Today · 2023-10 · 28 (10) · 103751

DOI: 10.1016/j.drudis.2023.103751 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Discovery Today, 2023-10. Verfasst von Giuseppe Astarita und 2 weiteren Autor:innen. Beteiligte Einrichtung: Georgetown University, Washington, DC, USA; Arkuda Therapeutics, Watertown, MA, USA. Electronic address: gastarita@gmail.com. Hauptthemen laut MEDLINE: Lipidomics, Lipids. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolomics and lipidomics have an increasingly pivotal role in drug discovery and development. In the context of drug discovery, monitoring changes in the levels or composition of metabolites and lipids relative to genetic variations yields functional insights, bolstering human genetics and (meta)genomic methodologies. This approach also sheds light on potential novel targets for therapeutic intervention. In the context of drug development, metabolite and lipid biomarkers contribute to enhanced success rates, promising a transformative impact on precision medicine. In this review, we deviate from analytical chemist-focused perspectives, offering an overview tailored to drug discovery. We provide introductory insight into state-of-the-art mass spectrometry (MS)-based metabolomics and lipidomics techniques utilized in drug discovery and development, drawing from the collective expertise of our research teams. We comprehensively outline the application of metabolomics and lipidomics in advancing drug discovery and development, spanning fundamental research, target identification, mechanisms of action, and the exploration of biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipidomicsLipidsHumansMetabolomicsBiomarkersDrug Discovery

Stichwörter der Autor:innen

biomarkersclinical trialsdrug discovery and developmentlipidomicslipidsmass spectrometrymetabolitesmetabolomicsprecision medicinetarget engagement

Substanzen

LipidsBiomarkers

Autor:innen und Institutionen

  • Georgetown University, Washington, DC, USA; Arkuda Therapeutics, Watertown, MA, USA. Electronic address: gastarita@gmail.com.
  • Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIAID NIH HHS
  • National Heart Lung and Blood Institute

Zitieren

APA

Astarita, G., Kelly, R. S., & Lasky-Su, J. (2023). Metabolomics and lipidomics strategies in modern drug discovery and development. Drug Discovery Today, 28(10), 103751. https://doi.org/10.1016/j.drudis.2023.103751

Vancouver

Astarita G, Kelly RS, Lasky-Su J. Metabolomics and lipidomics strategies in modern drug discovery and development. Drug Discovery Today. 2023;28(10):103751. doi:10.1016/j.drudis.2023.103751

BibTeX
@article{Astarita2023,
  author = {Astarita, Giuseppe and Kelly, Rachel S and Lasky-Su, Jessica},
  title = {Metabolomics and lipidomics strategies in modern drug discovery and development},
  journal = {Drug Discovery Today},
  year = {2023},
  volume = {28},
  number = {10},
  pages = {103751},
  doi = {10.1016/j.drudis.2023.103751}
}
Kostenlos starten →